ReviewPharmacogenomics and personalized medicine2019
Personalized treatment options for thyroid cancer: current perspectives.
Review in Pharmacogenomics and personalized medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Raman Spectroscopy as a Potential Adjunct of Thyroid Nodule Evaluation: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment.Journal of translational medicine · 2026Review
- Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.Diagnostics (Basel, Switzerland) · 2025Review
- EPHA5 promotes cell proliferation and inhibits apoptosis in Follicular Thyroid Cancer via the STAT3 signaling pathway.Oncogenesis · 2025Article
- Decoding the Crosstalk Between Heat Shock Proteins and Phytochemicals in Thyroid Nodule Regression: Mechanisms and Therapeutic Implications.Drug design, development and therapy · 2025Review
- Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine.Discover oncology · 2024Review
- Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020.Journal of diabetes and metabolic disorders · 2024Review
- Precision medicine path at personalized medicine research center/endocrinology and metabolism research institute: A systematic review.Journal of diabetes and metabolic disorders · 2024Review
- Impact of distant metastasis on overall survival and cancer specific survival of elderly patients with differentiated thyroid cancer.Scientific reports · 2024Article
- Personalized Management of Malignant and Non-Malignant Ectopic Mediastinal Thyroid: A Proposed 10-Item Algorithm Approach.Cancers · 2024Review
- Comparison of Clinical and Pathological Characteristics of Thyroid Cancer Surgery in the Pandemic Era.Medical journal of the Islamic Republic of Iran · 2024Article
- Advances in Molecular Profiling and Their Potential Influence on the Extent of Surgery in Well-Differentiated Thyroid Carcinoma (WDTC).Life (Basel, Switzerland) · 2023Article
- Survival after hemithyroidectomy versus total thyroidectomy in non-high-risk differentiated thyroid cancer: population-based analysis.BJS open · 2022Article
- Optimization of pre-analytical and analytical steps for DNA and RNA analysis of fresh cytology samples.Cancer medicine · 2022Article
- FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6.Experimental and therapeutic medicine · 2022Article
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.European journal of endocrinology · 2022Article
- Cause of Death Among Patients With Thyroid Cancer: A Population-Based Study.Frontiers in oncology · 2022Article
- Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.Journal of personalized medicine · 2021Review
- Impact of Lin28 on lymph node metastasis in papillary thyroid carcinoma.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is one of the most common endocrine malignancies, with increasing incidence all over the world. In spite of good prognosis for differentiated thyroid carcinoma, for an unknown reason, about 5-10% of the patients, the cancer will show aggressive behavior, develop metastasis, and be refractory to treatment strategies like radioactive iodine. Regarding the genetic information, each thyroid cancer patient can be considered as an individual unique one, with unique genetic information. Contrary to standard chemotherapy drugs, target therapy components aim at one or more definite molecular pathway on cancer cells, so their selection is underlying patient's genetic information. Nowadays, several mutations and rearrangements including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.